Cargando…

Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder

The aim of this post-hoc analysis was to determine whether early symptom improvement with extended release quetiapine (quetiapine XR) may predict treatment outcome in patients with major depressive disorder. Data were from 6, double-blind, placebo-controlled studies of quetiapine XR (2 fixed-dose an...

Descripción completa

Detalles Bibliográficos
Autores principales:	McIntyre, Roger S., Gorwood, Philip, Thase, Michael E., Liss, Charlie, Desai, Dhaval, Chen, Ji, Bauer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898901/ https://www.ncbi.nlm.nih.gov/pubmed/26474010 http://dx.doi.org/10.1097/JCP.0000000000000416

Ejemplares similares

A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014)

Quetiapine monotherapy for bipolar depression
por: Thase, Michael E
Publicado: (2008)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
por: Seetasith, Arpamas, et al.
Publicado: (2019)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011)

Role of extended release quetiapine in the management of bipolar disorders
por: Al Jurdi, Rayan K, et al.
Publicado: (2010)

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union
por: Brody, Robert S., et al.
Publicado: (2018)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili, Nizar
Publicado: (2012)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Rhabdomyolysis following Acute Extended-Release Quetiapine Poisoning: A Case Report
por: Liolios, Antonios, et al.
Publicado: (2012)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
por: Young, Allan H, et al.
Publicado: (2013)

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
por: Murasaki, Mitsukuni, et al.
Publicado: (2018)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott, Jean, et al.
Publicado: (2012)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Formulation development and optimization of polyox based quick dissolving film of quetiapine
por: Chaudhary, A. Sunita, et al.
Publicado: (2012)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage
por: Carta, Mauro Giovanni, et al.
Publicado: (2007)

Comparison of D(2) dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
por: Nord, Magdalena, et al.
Publicado: (2011)

Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies
por: Thase, Michael E.
Publicado: (2014)

Quetiapine Sustained Release in Treatment of Delirium Induced by Cerebral Metastasis
por: Messina, Antonino, et al.
Publicado: (2010)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre, Roger S, et al.
Publicado: (2021)

Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders
por: Hallinen, Taru, et al.
Publicado: (2012)

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
por: Kanba, Shigenobu, et al.
Publicado: (2019)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran, Anusha, et al.
Publicado: (2013)

Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles
por: Huang, Xiaomei, et al.
Publicado: (2018)

Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression
por: Datto, Catherine, et al.
Publicado: (2016)

Subcortical generalized myoclonus as a presenting symptom of quetiapine overdose
por: Fioravanti, Valentina, et al.
Publicado: (2022)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel, A
Publicado: (2013)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
por: McIntyre, Roger S., et al.
Publicado: (2015)

The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population
por: Pan, Pei-Yin, et al.
Publicado: (2015)

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
por: Rong, Carola, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9lagsr4o40g6jjqc1l32775lhg